Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)

Clinical trial NCT01805908 · TERMINATED

Trial details

NCT number

NCT01805908

Sponsor

Ontario Clinical Oncology Group (OCOG)

Status

TERMINATED

Phase

Phase 1

Study type

INTERVENTIONAL

Start date

2013-11-01

Primary completion

2016-06-01

Enrollment

3

View on ClinicalTrials.gov